Respiratory Medical Franchise, GSK, Durham, NC. RATIONALE: The OSMO study assessed whether patients with severe eosinophilic asthma (SEA) uncontrolled by omalizumab experienced improved asthma control when switched to mepolizumab. We investigated whether clinical outcomes after switching were associated with prior omalizumab treatment duration. METHODS: This was a post hoc analysis of the multicenter, open-label, single-arm, 32-week OSMO study (204471/NCT02654145). Patients with SEA uncontrolled by high-dose inhaled corticosteroids plus other controller(s) and omalizumab subcutaneously (SC) (> _4 months) were switched to mepolizumab 100 mg SC monthly. Patients had > _2 exacerbations in the year before screening and Asthma Control Questionnaire (ACQ)-5 score > _1.5 at screening and baseline visits. Study endpoints included LS mean change from baseline in ACQ-5 and St George's Respiratory Questionnaire (SGRQ) scores, pre-bronchodilator forced expiratory volume in 1 second (FEV 1 ), all at Week 32, and exacerbations comparing the year before screening to the study period. RESULTS: Of the 144 patients included, 50 (35%) received omalizumab for <1.5 years, 51 (35%) for 1.5-<4 years, and 43 (30%) for > _4 years. After switching to mepolizumab, clinically meaningful improvements in ACQ-5 score were observed in all three subgroups (LS mean change [ 
